Although non-tumor research based on CAR technology is still in its early stages, in-depth investigation into CAR-MSCs may offer novel insights and perspectives for the treatment of PE by modulating placental immune function and enhancing placental repair. Given that pregnant women constitute a special population, safety considerations must be fully prioritized in future research.
Wang et al. (Wed,) studied this question.